IMP3 and neoplasm: Those patients with tumor thickness ≤ 4.0 mm concomitant with positive IMP-3 expression had poorer OS, MSS, RFS and DMFS than ALM patients with thickness ≤ 4 mm and negative IMP-3 expression (Fig 3A–3D; P = 0.012, 0.048, 0.026 and 0.045, respectively; log rank test).